{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:24:51Z","timestamp":1776194691135,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clml.2023.08.018","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T02:03:01Z","timestamp":1693274581000},"page":"917-923.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0051-7790","authenticated-orcid":false,"given":"Dane R.","family":"Van Domelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohad S.","family":"Bentur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"\u0160pi\u010dka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.08.018_bib0001","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.018_bib0002","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.018_bib0003","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.08.018_bib0004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.018_bib0005","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.018_bib0006","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41416-021-01608-2","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2023.08.018_bib0007","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/blood-2021-148759","article-title":"Once weekly oral selinexor, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma","volume":"138","author":"White","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.018_bib0008","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.08.018_bib0009","series-title":"UpToDate","article-title":"Dosing of anticancer agents in adults","author":"Eaton","year":"2023"},{"key":"10.1016\/j.clml.2023.08.018_bib0010","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2021-146003","article-title":"Clinical outcomes in patients (Pts) with dose reduction of selinexor in combination with bortezomib, and dexamethasone (XVd) in previously treated multiple myeloma from the Boston study","volume":"138","author":"Jagannath","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.018_bib0011","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.08.018_bib0012","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","article-title":"Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma","volume":"87","author":"Kvam","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.08.018_bib0013","unstructured":"XPOVIOTM (Selinexor) Prescribing Information. Karyopharm Therapeutics Inc.; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212306s000lbl.pdf"},{"key":"10.1016\/j.clml.2023.08.018_bib0014","doi-asserted-by":"crossref","first-page":"e899038f","DOI":"10.1097\/01.HS9.0000970832.89903.8f","article-title":"P982: Efficacy and safety of 40 mg vs 60 mg of once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"7","author":"White","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2023.08.018_bib0015","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.2021.39.15_suppl.1005","article-title":"Treatment-related side effects and views about dosage assessment to sustain quality of life: results of an advocate-led survey of patients with metastatic breast cancer (MBC)","volume":"39","author":"Loeser","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.018_bib0016","doi-asserted-by":"crossref","first-page":"e1807","DOI":"10.1200\/OP.22.00427","article-title":"Oncologists' perspectives on individualizing dose selection for patients with metastatic cancer","volume":"18","author":"Jimenez","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2023.08.018_bib0017","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2023.08.018_bib0018","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-09-2684","article-title":"Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse","volume":"16","author":"Jain","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.08.018_bib0019","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jgo.2012.03.002","article-title":"Clinical trial design in older adults with cancer\u2014the need for new paradigms","volume":"3","author":"Lichtman","year":"2012","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2023.08.018_bib0020","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology\u2014when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.018_bib0021","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-021-06215-6","article-title":"Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer","volume":"188","author":"Kristensen","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clml.2023.08.018_bib0022","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-020-00771-5","article-title":"Impact of dose reduction on efficacy: implications of exposure-response analysis of palbociclib","volume":"16","author":"Zheng","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.clml.2023.08.018_bib0023","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clml.2022.01.014","article-title":"Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from International Myeloma Foundation Expert Roundtable","volume":"22","author":"Nooka","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.08.018_bib0024","author":"US Food and Drug Administration"},{"key":"10.1016\/j.clml.2023.08.018_bib0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.08.018_bib0026","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/codi.15295","article-title":"Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy","volume":"22","author":"Musoro","year":"2020","journal-title":"Colorectal Dis"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:20Z","timestamp":1761871400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2152265023002793"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}